肺癌组织中CD105与Nestin的表达

EXPRESSION OF CD105 AND Nestin IN LUNG CANCER

①目的以CD105为新生血管标记物,研究及特异性识别肿瘤组织中的新生血管。②方法采用免疫组织化学双标技术,检测45例新鲜肺癌及其癌旁组织中CD105、Nestin、αSMactin的表达情况;应用免疫荧光技术,检测CD105与Nestin表达的差异。③结果肺癌及其癌旁组织中CD105、Nestin的表达差异有显著性(t=20.70、54.80,P<0.001);肺癌组织中CD105和Nestin表达强度的差异也具有显著性(t=3.08,P<0.01),前者的表达高于后者;肺癌组织中CD105的表达强度与肿瘤大小、淋巴结转移有明显相关性(t=2.871、3.730,P<0.05),Nestin的表达强度与病人的临床病理特征无明显相关性(P>0.05)。αSMactin主要表达于陷于肿瘤组织内及癌旁组织中的原有成熟血管的管壁,而在肿瘤的新生血管区少有阳性表达。④结论CD105可作为新生血管的标记物用于抗肿瘤血管形成的研究和治疗;Nestin临床应用价值有待于进一步研究;新生血管内皮标记物与αSMactin的免疫组化双标染色可更为直观地显示肿瘤组织中的新生血管。

Objective To provide a new marker of ECs to identify the newborn vessels in tumor tissue. Methods Double immunohistochemistry was used to identify the expression of CD105, Nestin and α-SM-actin in fresh tumor and peri-tumor tissue of 45 cases of lung cancer. Immunofluorescence was applied to identify the difference of expression between CD105 and Nestin. Results There were significant differences in the expression of CD105 between the tumor tissue and non-tumor tissue of the same patient（P〈0. 001）, and so was the expression of Nestin （P〈0.001）. Statistic significance was detected between the expression of CD105 and Nestin in the tumor tissue of the same patient. Conctusion CD105, as a marker of angiogenic ECs, can be applied to the research of antiangiogenesis and bear therapeutic potential in patients with lung cancer. Nestin has little relation to metastasis of lymphonode, and its clinical application needs to be further investigated. It＇s easy to detect new born vessels in tumor tissue with double immunohistochemical staining for α-SM-actin and markers of angiogenesis.